Retrospective Analysis of Antimicrobial Resistance Trends in Pseudomonas Aeruginosa and Acinetobacter Baumannii

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Oct 14

PMID 39398730

Authors

Nandhini Ravella Venkatasubramanyam

Subbalakshmi Easwaran

Neelusree Prabhakaran

Affiliations

Soon will be listed here.

Abstract

Introduction: The rise of antibiotic resistance poses a critical challenge to public health, particularly in managing infections caused by non-fermenting bacteria such as and This study aimed to determine the prevalent multi-drug resistance among non-fermentative Gram-negative bacteria isolated from hospitalized patients in a tertiary care center.

Material And Methods: A retrospective analysis was undertaken using one year of data from 2022 to 2023 to evaluate the antimicrobial resistance (AMR) profiles of and . The study assessed antibiotic resistance patterns, including piperacillin/tazobactam, carbapenems (imipenem, meropenem), ciprofloxacin, and colistin.

Results: The analysis revealed resistance of to various antibiotics shows that piperacillin/tazobactam exhibited the highest resistance rate at 32% (181/565), while colistin exhibits the lowest at 5.6% (32/565). For , the resistance varies significantly among antibiotics, with piperacillin/tazobactam and ciprofloxacin showing the highest resistance rates at 56.8% (128/225) and 68% (153/225), respectively. In contrast, colistin is highly effective, with only 0.8% (2/225) resistance, and amikacin also demonstrates low resistance at 9.7% (22/225).

Conclusion: The growing trend of multi-drug and extensive drug resistance among non-fermenters such as and necessitates urgent action. Establishing strict antibiotic policies, continuous monitoring of resistance patterns, and investment in antimicrobial research are imperative to combat the limited treatment options and manage these pathogens effectively.

Citing Articles

Towards New Scaffolds for Antimicrobial Activity-In Silico/In Vitro Workflow Introducing New Lead Compounds.

Mangana M, Lambrinidis G, Kostakis I, Kalpaktsi I, Sagnou M, Nicolaou C Antibiotics (Basel). 2025; 14(1).

PMID: 39858297 PMC: 11763081. DOI: 10.3390/antibiotics14010011.

References

Yadav S, Bhujel R, Mishra S, Sharma S, Sherchand J . Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal. BMC Res Notes. 2020; 13(1):319. PMC: 7330544. DOI: 10.1186/s13104-020-05163-6. View

Gales A, Jones R, Forward K, Linares J, Sader H, Verhoef J . Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program.... Clin Infect Dis. 2001; 32 Suppl 2:S104-13. DOI: 10.1086/320183. View

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

van Duin D, Paterson D . Multidrug-Resistant Bacteria in the Community: An Update. Infect Dis Clin North Am. 2020; 34(4):709-722. PMC: 8713071. DOI: 10.1016/j.idc.2020.08.002. View

Iskandar K, Murugaiyan J, Hammoudi Halat D, El Hage S, Chibabhai V, Adukkadukkam S . Antibiotic Discovery and Resistance: The Chase and the Race. Antibiotics (Basel). 2022; 11(2). PMC: 8868473. DOI: 10.3390/antibiotics11020182. View

Kuti J, Wang Q, Chen H, Li H, Wang H, Nicolau D . Defining the potency of amikacin against , and derived from Chinese hospitals using CLSI and inhalation-based breakpoints. Infect Drug Resist. 2018; 11:783-790. PMC: 5975598. DOI: 10.2147/IDR.S161636. View

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet D . Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2017; 18(3):318-327. DOI: 10.1016/S1473-3099(17)30753-3. View

El Chakhtoura N, Saade E, Iovleva A, Yasmin M, Wilson B, Perez F . Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy. Expert Rev Anti Infect Ther. 2018; 16(2):89-110. PMC: 6093184. DOI: 10.1080/14787210.2018.1425139. View

Golli A, Cristea O, Zlatian O, Glodeanu A, Balasoiu A, Ionescu M . Prevalence of Multidrug-Resistant Pathogens Causing Bloodstream Infections in an Intensive Care Unit. Infect Drug Resist. 2022; 15:5981-5992. PMC: 9575466. DOI: 10.2147/IDR.S383285. View

10.

Rice L . Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006; 119(6 Suppl 1):S11-9. DOI: 10.1016/j.amjmed.2006.03.012. View

11.

Basak S, Singh P, Rajurkar M . Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. J Pathog. 2016; 2016:4065603. PMC: 4749793. DOI: 10.1155/2016/4065603. View

12.

Salam M, Al-Amin M, Salam M, Pawar J, Akhter N, Rabaan A . Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare (Basel). 2023; 11(13). PMC: 10340576. DOI: 10.3390/healthcare11131946. View

13.

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

14.

Weiner L, Webb A, Limbago B, Dudeck M, Patel J, Kallen A . Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016; 37(11):1288-1301. PMC: 6857725. DOI: 10.1017/ice.2016.174. View

15.

Kateete D, Nakanjako R, Namugenyi J, Erume J, Joloba M, Najjuka C . Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago Hospital in Kampala, Uganda (2007-2009). Springerplus. 2016; 5(1):1308. PMC: 4978656. DOI: 10.1186/s40064-016-2986-7. View

16.

Perez F, Hujer A, Hujer K, Decker B, Rather P, Bonomo R . Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007; 51(10):3471-84. PMC: 2043292. DOI: 10.1128/AAC.01464-06. View

17.

Novovic K, Jovcic B . Colistin Resistance in Molecular Mechanisms and Epidemiology. Antibiotics (Basel). 2023; 12(3). PMC: 10044110. DOI: 10.3390/antibiotics12030516. View

18.

Al-Tamimi M, Albalawi H, Alkhawaldeh M, Alazzam A, Ramadan H, Altalalwah M . Multidrug-Resistant in Jordan. Microorganisms. 2022; 10(5). PMC: 9144680. DOI: 10.3390/microorganisms10050849. View

19.

Bush K, Bradford P . β-Lactams and β-Lactamase Inhibitors: An Overview. Cold Spring Harb Perspect Med. 2016; 6(8). PMC: 4968164. DOI: 10.1101/cshperspect.a025247. View